Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma

Annals of Oncology

Volumn 14, Issue 5, 2003, Pages 737-744

  Hosing, C ^a   Saliba, R M ^a   McLaughlin, P ^a   Andersson, B ^a   Rodriguez, M A ^a   Fayad, L ^a   Cabanillas, F ^a   Champlin, R E ^a   Khouri, I F ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Allogeneic stem cell transplantation; Autologous stem cell transplantation; Indolent non Hodgkin's lymphoma

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; HLA ANTIGEN; MELPHALAN; MESNA; METHOTREXATE; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS;

ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DONOR; DRUG MEGADOSE; FEMALE; FOLLOW UP; GENDER; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR REGRESSION;

ADULT; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037767207     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg200     Document Type: Article

References (30)

1. Horning SJ. Treatment approaches to the low-grade lymphomas. Blood 1994; 83: 881-884.
2. Romaguera JE, McLaughlin P, North L et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 1991; 9: 762-769.
3. Rohatiner AZS, Johnson PWM, Price CGA et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177-1184.
4. Schouten HC, Raemaekers JJ, Kluin-Nelemans HC et al. High-dose therapy followed by bone marrow transplantation for relapsed follicular non-Hodgkin's lymphoma: Dutch HOVON Group. Ann Hematol 1996; 73: 273-277.
5. Bierman PJ, Vose JM, Anderson JR et al. High dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445-450.
6. Freedman AS, Neuberg D, Mauch P et al. Long term follow up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999: 94: 3325-3333.
7. Cao TM, Horning SJ, Negrin RS et al. High-dose therapy and autologous hematopoietic-stem cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001; 7: 294-301.
8. Horning SJ, Negrin RS, Hoppe RT et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001; 97: 404-409.
9. Freedman A, Gribben J, Neuberg D et al. High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780-2786.
10. Apostolidis J, Gupta RK, Grenzelias D et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow up. J Clin Oncol 2000; 18: 527-536.
11. van Besien KW, Khouri IF, Giralt S et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol 1995; 13: 1096-1102.
12. Reading CL, Thomas MW, Hickey CM et al. Magnetic affinity colloid (MAC) cell separation of leukemia cells from autologous bone marrow aspirates. Leuk Res 1987; 11: 1067-1077.
13. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
14. Wilcoxon F. Individual comparisons by ranking methods. Biometrics 1945; 1: 80-83.
15. StataCorp. Stata Statistical Software: release 7.0. College Station, TX: Stata Corporation 2001
16. Verdonck L. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience. Leuk Lymphoma 1999; 34: 129-136.
17. Attal M, Socié G, Molina L et al. Allogeneic bone marrow transplantation for refractory and recurrent follicular lymphoma: a case matched analysis with autologous transplantation from the French bone marrow transplant group registry data. Blood 1997; 90 (Suppl 1): 255a.
18. Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
19. van Besien KW, de Lima M, Giralt S et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of a graft versus lymphoma effect. Bone Marrow Transplant 1997; 19: 977-982.
20. Stein RS, Greer JP, Goodman S et al. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small-cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplant 1999; 23: 227-233.
21. Khouri I, Keating M, Körbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
22. Khouri I, Saliba R, Giralt S et al. Allogeneic hematopoietic transplantation for indolent lymphomas: improved outcome with non-myeloablative versus high dose chemotherapy (HDCT) regimens. Blood 2000; 96: 853a.
23. Khouri IF, Saliba RM, Giralt S et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595-3599.
24. Pedersen-Bjergaard J, Pedersen M, Myhre I et al. High-risk of therapy-related leukemia after BEAM chemotherapy and autologous stem-cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM transplantation procedure. Leukemia 1997; 11: 1654-1660.
25. Micallef INM, Lillington DM, Apostolidis J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947-955.
26. Hosing C, Munsell M, Yazji S et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 450-459.
27. Press O, Eary J, Applebaum F et al. Phase II trial of 131-B1 (anti CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet 1995; 346: 336-340.
28. Liu S, Eary J, Petersdorf S et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16: 3270-3278.
29. Buckstein R, Imrie K, Spaner D et al. High frequency of molecular remissions associated with rituxan or interferon immunotherapy following ASCT for follicular NHL. Blood 2000; 96: 3418a.
30. Magni M, DiNicola M, Devizzi L et al. Successful in vivo purging of CD 34 containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864-869.